Ostrovskaya R U, Ozerova I V, Gudascheva T A, Kapitsa I G, Ivanova E A, Voronina T A, Seredenin S B
V.V. Zakusov Institute of Pharmacology, Russian Academy of Medical Sciences, Moscow, Russia.
Bull Exp Biol Med. 2013 Jan;154(3):334-8. doi: 10.1007/s10517-013-1944-4.
We studied the effects of new nootropic and neuroprotective drug Noopept (N-phenylacetyl-L-prolylglycine ethyl ester) in various dosage regimens on the dynamics of glycemia, body weight, and pain sensitivity in rats receiving diabetogenic toxin streptozotocin. In experimental diabetic rats, Noopept alleviated glycemia and weight loss and normalized enhanced pain sensitivity. The normalizing effect of Noopept was most pronounced when it was administered as a preventive agent prior to injection of the toxin. Both preventive and therapeutic administration of Noopept (delayed injections included) significantly weakened the examined metabolic effects of diabetogenic toxin. Possible mechanisms of the antidiabetic action of Noopept are analyzed.
我们研究了新型促智和神经保护药物诺吡酯（N-苯基乙酰基-L-脯氨酰甘氨酸乙酯）在不同给药方案下，对接受致糖尿病毒素链脲佐菌素的大鼠血糖动态、体重和疼痛敏感性的影响。在实验性糖尿病大鼠中，诺吡酯减轻了血糖升高和体重减轻，并使增强的疼痛敏感性恢复正常。当诺吡酯作为预防剂在注射毒素之前给药时，其归一化作用最为明显。诺吡酯的预防性和治疗性给药（包括延迟注射）均显著减弱了致糖尿病毒素所检测到的代谢作用。分析了诺吡酯抗糖尿病作用的可能机制。
